Daisuke Omoto
Kitakyushu, 8078555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Journal: Diagnostics (Basel, Switzerland)
Published: December 27, 2021
A Retrospective Study of Superficial Type Atypical Lipomatous Tumor.
Journal: Frontiers in medicine
Published: September 24, 2020
High S100A2 expression in keratinocytes in patients with drug eruption.
Journal: Scientific reports
Published: August 13, 2020
The prevalence of urticaria, hand eczema, atopic dermatitis and asthma among bakers in Japan.
Journal: European journal of dermatology : EJD
Published: January 07, 2020
Endometriosis in the setting of Muckle-Wells syndrome treated with an IL-1β antagonist.
Journal: European journal of dermatology : EJD
Published: May 17, 2017
Psoriatic Erythroderma Caused by Terbinafine: A Possible Pathogenetic Role for IL-23.
Journal: Journal of investigational allergology & clinical immunology
Published: February 18, 2017
Lichenoid drug eruption caused by adalimumab: a case report and literature review.
Journal: European journal of dermatology : EJD
Published: October 26, 2016
Drug eruption caused by secukinumab.
Journal: European journal of dermatology : EJD
Published: October 18, 2016
A possible role of IL-23-producing cells in a patient with psoriasiform drug eruption due to tazobactam and piperacillin hydrate: a case study and literature review.
Journal: European journal of dermatology : EJD
Published: October 18, 2016
Maculopapular type drug eruption caused by fosphenytoin.
Journal: European journal of dermatology : EJD
Published: August 23, 2016
A possible role of IL-23/IL-17 axis in patients with lupus miliaris disseminatus faciei.
Journal: Clinical immunology (Orlando, Fla.)
Published: July 15, 2016
Last Updated: 09/26/2026